Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Pharmaceuticals
- Disease
- Therapeutic
- Pain
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5939
Indiplon (INN and USAN) is a nonbenzodiazepine, hypnotic sedative being developed in 2 formulations – an immediate release product for sleep onset and a modified-release version for sleep maintenance.
U.S. 6,399,621 expires 8/9/2020
U.S. 4,900,836 expires 2/13/2007
U.S. 4,521,422 expires 6/23/2003
IPSCIO Record ID: 2518
Indiplon is a nonbenzodiazepine, hypnotic sedative was developed in 2 formulations – an immediate release product for sleep onset and a modified-release version for sleep maintenance. Indiplon is a unique nonbenzodiazepine agent that acts on a specific site of the GABAA receptor. It has been shown to bind selectively to the specific subtype of GABAA receptors within the brain believed to be responsible for promoting sleep.
IPSCIO Record ID: 5590
UNITED STATES
U.S. 4,196,120 – expires 4/1/97
U.S. 4,231,935 – expires 11/4/97
U.S. 4,435,419 – expires 7/1/01
USSN 08/122,856 – pending
USSN 08/414,180 – pending
CL 216,303
UNITED STATES
U.S. 4,196,120 – expires 4/1/97
U.S. 4,231,935 – expires 11/4/97
U.S. 4,435,419 – expires 7/1/01
USSN 08/122,856 – pending
USSN 08/414,180 – pending
CL 273,547
UNITED STATES
U.S. 4,521,422 – expires 6/23/03
4,196,120 Substituted 3-azabicyclo[3.1.0 hexanes, acid addition salts, method of use and method of preparation are described. The compounds have anxiolytic and analgesic activity.
IPSCIO Record ID: 2721
Under the Licensee's original License Agreement with the Licensor for eszopiclone, dated October 1999, the Licensee is obligated to pay a royalty on sales of Lunesta in the United States and, as part of the July 2004 amendment to this Agreement, the Licensee permitted the Licensor, to assign the royalty obligation to a third party in exchange for the right to read and reference the Licensor's regulatory filings related to zopiclone outside of the U.S. for the purpose of development and regulatory registration of eszopiclone outside of the United States. The Licensor has assigned to the Licensee the foreign counterparts to the U.S. patent covering eszopiclone and its therapeutic use.
Licensor owns U.S. Patent Application Serial No. 09/124,651, relating to use of(+) zopiclone, and certain know-how relating to the use of zopiclone, its enantiomers and metabolites.
Licensee is the assignee of U.S. Patent No. 5,786,357, relating to use of ( +) zopiclone, and is interested in developing pharmaceutical products containing(+) zopiclone as an active ingredient for sale in the United States.
Product shall mean any composition which contains Compound as an active ingredient, including any composition which contains Compound and one or more other active ingredients.
Compound shall mean the compound known as(+) zopiclone, also identified by the chemical name(+) 6-{5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-SH-pyrrolo [3,4b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate or ( +) 6-(5-chloropyri-2-dyl)- 5-(4-methylpiperazin-l-yl) carbonyloxy-7-oxo-6,7-dihydro-SH-pyrrolo [3,4b] pyrazine.
Zopiclone Technology shall mean technology specifically related to Compound, the racemate or the other enantiomer thereof, or metabolites of any of the foregoing.
Licensee is a leading specialty pharmaceutical company focused on the cost-effective development of safer, purer and more effective drugs that are improved versions of widely-prescribed pharmaceutical compounds. Zopiclone is used in the treatment of insomnia.
IPSCIO Record ID: 253957
Licensor grants an exclusive option to obtain exclusive, even as to Licensor, right and license, with the right to sublicense, under the MR Program Data to identify, make, have made, use, develop, sell, offer for sale, have sold and import MR Product in the Field of Use in the Territory and make, have made, use, sell, offer for sale, have sold and import Indiplon in bulk, active ingredient form in the Territory.
In the event that Licensee determines to use the Licensor Trademarks, Licensor grants the exclusive license and right, free of charge, to use the Licensor Trademarks solely and exclusively for the purpose of Commercialization of Products in the Territory in accordance with this Agreement and shall register the Licensees license of the Licensor Trademark at the Japan Patent Office.
Indiplon shall mean the nonbenzodiazepine insomnia agent compound.
IR Product shall mean the immediate release tablet, capsule or other formulation of Indiplon whose release profiles are proved to be equivalent.
MR Product shall mean the modified or extended release tablet, capsule or other formulation of Indiplon.
